SunGlowInnovations

SunGlow Innovations

Evidence

The experimental and observational record behind the clinical development plan.

Tissue and reaction studies

Whole blood and liver tissue were used to examine spatial reaction behavior and the apparent boundary of the contact zone.

Investigator’s Brochure v1.0 §§4.1–4.2, Figures 4-1 and 4-3–4-5

Animal models

Mouse observations evaluated route-specific effects, including local vascular injury.

Investigator’s Brochure v1.0 §§4.1, 4.3, Figures 4-2, 4-7 and 4-8

Companion animal observations

The investigator brochure summarizes 22 animals with spontaneous tumors: 19 dogs and 3 cats. Clinical signs and local tissue changes varied by case.

Investigator’s Brochure v1.0 §5, Figures 5-1–5-5 · IND Module 2.5, Table 6-1

Pet oncology

Historical human observations

Historical records cover approximately 25 patients. Available documentation describes local tissue changes and both local and serious adverse events.

Investigator’s Brochure v1.0 §§6.1–6.3, Table 6-1 and Figures 6-1–6-6 · IND Module 2.5, Tables 3-1 and 4-1

Imaging observations

Historical observations describe ultrasound and CT visualization of delivery distribution. The Phase 1 plan evaluates containment separately from follow-up non-viability.

Investigator’s Brochure v1.0 §§2.3, 4.2 and 7.3, Figure 4-6 · Protocol v3.0 §§3, 7 and 10.3

Safety and clinical pharmacology

The clinical plan combines adverse-event surveillance with assays for reaction products and hematologic markers.

Investigator’s Brochure v1.0 §§4.4, 6.3, 7.7 and 8 · Protocol v3.0 §§8–9 · 2026-11-19

Phase 1 clinical development

Proposed assessments cover safety, containment, local activity and durability.

Protocol v3.0 §§3–5, 9 and 10 · 2026-11-19